SAN DIEGO, Feb. 02, 2018 -- After Tuesday’s State of the Union Address, The Recover examines Trump’s message to lower prescription costs and fight for the dying rights of those with terminal conditions.

Trump’s Promise To Lower Prescription Drug Costs

In his speech he addressed the “Right to Try” Legislation that was proposed but is waiting on approval from the FDA. "We also believe that patients with terminal conditions should have access to experimental treatments that could potentially save their lives," the president said.

"People who are terminally ill should not have to go from country to country to seek a cure — I want to give them a chance right here at home. It is time for the Congress to give these wonderful Americans the 'right to try,'" he says.

The prescription drug cost has been rising in recent years, with medications dramatically increasing 44% since 2003, and continues to grow with out interference. Trump proposes to prevent that from happening under his administration, but without a clear plan.

"One of my greatest priorities is to reduce the price of prescription drugs. In many other countries, these drugs cost far less than what we pay in the United States," Trump stated.

"And it is very, very unfair," he said. "That is why I have directed my administration to make fixing the injustice of high drug prices one of our top priorities. Prices will come down."

The President will also have to address the issue that some of these prescription drugs have led to the opioid problem the country faces. Other pain relievers and stimulant prescription drugs can be misused and can cause an addiction to the user.

Alex Azar was in attendance at the address, a former drug company executive, lobbyist and spokesperson who has been sworn in as Secretary of Health and Human Services under President Trump's cabinet. Mr. Azar’s former profession brings into question how someone from that industry could possibly have a hand in disrupting their profit and helping the people of America. While introducing Azar, Trump mentioned several times that he shared his desire in reducing prescription drug prices.

Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.